The FDA has approved updated labeling for Sublocade (buprenorphine extended-release) injection to include a rapid induction protocol and alternative injection sites.
Selarsdi (ustekinumab-aekn; Teva and Alvotech), and Yesintek (ustekinumab-kfce; Biocon Biologics), all biosimilars to Stelara (ustekinumab; Johnson & Johnson) are now available in the US.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback